Clinical Trials on IDH1-mutant Cholangiocarcinoma in United Kingdom

Total 440 results

Servier Bio-Innovation LLC
Institut de Recherches Internationales Servier

Recruiting

Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant Cholangiocarcinoma

IDH1-mutant Cholangiocarcinoma

United States, United Kingdom
University of Chicago

Recruiting

A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms

Myeloproliferative Neoplasm | Blood Cancer | IDH2 Gene Mutation | IDH1 Mutation | IDH Mutation

United States
Rigel Pharmaceuticals
Nationwide Children's Hospital

Not yet recruiting

Study of Olutasidenib and Temozolomide in HGG

Astrocytoma | High Grade Glioma | Oligodendroglioma | Diffuse Intrinsic Pontine Glioma | Diffuse Midline Glioma, H3 K27M-Mutant | WHO Grade III Glioma | Metastatic Brain Tumor | Spinal Tumor | Astrocytoma, Grade III | Astrocytoma, Grade IV | IDH1 Mutation | WHO Grade IV Glioma | Thalamus Tumor | IDH1 R132 | IDH1 R132C | IDH1 R132H and other conditions

United States, Australia, United Kingdom, Canada, Germany, Netherlands
National Cancer Institute (NCI)

Active, not recruiting

Telaglenastat With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma

Astrocytoma, IDH-Mutant, Grade 2 | Astrocytoma, IDH-Mutant, Grade 3

United States
Massachusetts General Hospital
Agios Pharmaceuticals, Inc.

Completed

IDH1 Inhibition Using Ivosidenib as Maintenance Therapy for IDH1-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation

IDH1 Mutation Myeloid Neoplasms

United States
National Cancer Institute (NCI)

Suspended

A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden

Diffuse Glioma | Secondary Glioblastoma | Glioblastoma, IDH-Wildtype | Astrocytoma, IDH-Mutant, Grade 4

United States, Puerto Rico
Forma Therapeutics, Inc.

Completed

A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation

Cohort 1a and 1b: Glioma (Advanced Gliomas and Glioblastoma Multiforme) | Cohort 2a and 2b: Hepatobiliary Tumors (Hepatocellular Carcinoma, Bile Duct Carcinoma, Intrahepatic Cholangiocarcinoma, Other Hepatobiliary Carcinomas) | Cohort 3a and 3b: Chondrosarcoma | Cohort 4a and 4b: Intrahepatic... and other conditions

United States, Korea, Republic of, Australia, United Kingdom, Spain, France
Memorial Sloan Kettering Cancer Center
Array BioPharma

Completed

A Study of Binimetinib and Encorafenib in Advanced BRAF Mutant Cancers

Advanced BRAF Mutant Cancers

United States
University College, London

Recruiting

CAR T Cells to Target GD2 for DMG (CARMIGO)

Diffuse Midline Glioma, H3 K27M-Mutant

United Kingdom
Massachusetts General Hospital
GlaxoSmithKline

Recruiting

Niraparib In Recurrent IDH 1/2 Gliomas

Recurrent Glioma | Low-grade Glioma | Glioma, Malignant | IDH2 Gene Mutation | IDH1 Mutation

United States
Mayo Clinic
National Cancer Institute (NCI)

Not yet recruiting

Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma

Stage III Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Unresectable Intrahepatic Cholangiocarcinoma | Locally Advanced Intrahepatic Cholangiocarcinoma | Oligometastatic Intrahepatic Cholangiocarcinoma

United States
M.D. Anderson Cancer Center

Active, not recruiting

Hypofractionated Radiation Therapy and Bintrafusp Alfa for the Treatment of Advanced Intrahepatic Cholangiocarcinoma

Stage III Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Metastatic Intrahepatic Cholangiocarcinoma | Locally Advanced Intrahepatic Cholangiocarcinoma

United States
NRG Oncology
National Cancer Institute (NCI)

Active, not recruiting

Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients With IDH Mutant Grade II or III Glioma

Glioma | Oligoastrocytoma | Anaplastic Astrocytoma | Oligodendroglioma | Diffuse Astrocytoma | WHO Grade III Glioma | IDH2 Gene Mutation | IDH1 Gene Mutation | 1p/19q Co-deletion

United States
Emory University
National Cancer Institute (NCI)

Withdrawn

Preoperative Nab-paclitaxel, Cisplatin, and Gemcitabine Chemotherapy With or Without Infigratinib Targeted Therapy for the Treatment of Resectable Intrahepatic Cholangiocarcinoma, The OPTIC Trial

Stage II Intrahepatic Cholangiocarcinoma AJCC v8 | Stage III Intrahepatic Cholangiocarcinoma AJCC v8 | Resectable Intrahepatic Cholangiocarcinoma | Stage 0 Intrahepatic Cholangiocarcinoma AJCC v8 | Stage I Intrahepatic Cholangiocarcinoma AJCC v8

United States
University of Kansas Medical Center
National Cancer Institute (NCI)

Recruiting

Sacituzumab Govitecan for the Treatment for Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma

Stage III Intrahepatic Cholangiocarcinoma AJCC v8 | Metastatic Cholangiocarcinoma | Locally Advanced Cholangiocarcinoma | Stage III Hilar Cholangiocarcinoma AJCC v8 | Stage IV Hilar Cholangiocarcinoma AJCC v8 | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Recurrent Cholangiocarcinoma

United States
Emory University
National Cancer Institute (NCI); National Institutes of Health (NIH); Celgene

Active, not recruiting

Gemcitabine, Cisplatin, and Nab-Paclitaxel Before Surgery in Patients With High-Risk Liver Bile Duct Cancer

Resectable Cholangiocarcinoma | Stage IB Intrahepatic Cholangiocarcinoma AJCC v8 | Stage II Intrahepatic Cholangiocarcinoma AJCC v8 | Stage III Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8

United States
RedHill Biopharma Limited

Completed

A Study of ABC294640 (Yeliva ®) Alone and in Combination With Hydroxychloroquine Sulfate in Treatment of Patients With Advanced Cholangiocarcinoma

Cholangiocarcinoma | Cholangiocarcinoma Non-resectable | Cholangiocarcinoma, Perihilar | Cholangiocarcinoma, Extrahepatic | Cholangiocarcinoma, Intrahepatic

United States
University of Oxford

Recruiting

Deep Liver Phenotyping and Immunology Study (DELPHI)

Hepatocellular Carcinoma | Cholangiocarcinoma

United Kingdom
Massachusetts General Hospital

Terminated

A Pilot Study of Neoadjuvant Therapy With Gemcitabine and Cisplatin in Patients With Resectable or Unresectable Intrahepatic Cholangiocarcinoma

Resectable Intrahepatic Cholangiocarcinoma | Unresectable Intrahepatic Cholangiocarcinoma

United States
Amgen

Active, not recruiting

A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)

KRAS p.G12C Mutant Advanced Solid Tumors

United States, France, Canada, Spain, Belgium, Korea, Republic of, Austria, Australia, Hungary, Greece, Germany, Japan, Romania, Switzerland, Brazil, Portugal
Institut de Recherches Internationales Servier

Completed

Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy) (ClarIDHy)

Metastatic Cholangiocarcinoma | Advanced Cholangiocarcinoma

United States, Spain, Korea, Republic of, Italy, France, United Kingdom
Sirtex Medical

Completed

SIRT Followed by CIS-GEM Chemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma (SIRCCA)

Intrahepatic Cholangiocarcinoma

France, United Kingdom, Belgium, Australia, Spain, United States, Italy, Netherlands
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Terminated

Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma

Metastatic Cholangiocarcinoma | Unresectable Cholangiocarcinoma | Advanced Cholangiocarcinoma

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI); BeiGene

Completed

BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations

Recurrent Glioblastoma | Recurrent WHO Grade III Glioma | Recurrent WHO Grade II Glioma | IDH1 Mutation | IDH2 Mutation

United States
Rutgers, The State University of New Jersey

Recruiting

Liver Transplantation in Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma | Cholangiocarcinoma, Intrahepatic

United States
Royal Marsden NHS Foundation Trust
Merck KGaA, Darmstadt, Germany; University of Oxford; University of Surrey

Terminated

Avelumab Plus 5-FU Based Chemotherapy as Adjuvant Treatment for Stage 3 MSI-High or POLE Mutant Colon Cancer (POLEM)

Microsatellite Instability | Stage III Colon Cancer | POLE Exonuclease Mutant Colon Cancer

United Kingdom
University of Louisville

Withdrawn

A Study of Cisplatin or Carboplatin With Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Patients With Resected or Ablation Intra-Hepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma

United States
OHSU Knight Cancer Institute
Oregon Health and Science University

Active, not recruiting

mFOLFIRINOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone With Systemic mFOLFIRI for Unresectable Liver-dominant Intrahepatic Cholangiocarcinoma

Stage III Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8 | Liver and Intrahepatic Bile Duct Carcinoma | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Unresectable Intrahepatic Cholangiocarcinoma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Withdrawn

Capecitabine and Y-90 Radioembolization in Treating Patients With Advanced Bile Duct Cancer in the Liver That Cannot Be Removed by Surgery

Bile Duct Adenocarcinoma | Stage III Intrahepatic Cholangiocarcinoma | Stage IVA Intrahepatic Cholangiocarcinoma | Stage IVB Intrahepatic Cholangiocarcinoma

United States
Yale University

Terminated

A Trial of Systemic Chemotherapy in Combination With Conventional Transarterial Chemoembolization in Patients With Advanced Intra-Hepatic Cholangiocarcinoma

Unresectable Intrahepatic Cholangiocarcinoma

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
AstraZeneca; Syndax Pharmaceuticals

Completed

Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma

Unresectable Intrahepatic Cholangiocarcinoma

United States
Robert C. Martin
University of Louisville

Completed

Drug-Eluting Bead, Irinotecan Therapy for Unresectable Intrahepatic Cholangiocarcinoma w/Concomitant Gemcitabine and Cisplatin or Carboplatin (DELTIC)

Unresectable Intrahepatic Cholangiocarcinoma

United States
Tyra Biosciences, Inc

Recruiting

Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations (SURF201)

Solid Tumor | Intrahepatic Cholangiocarcinoma | Metastatic Cholangiocarcinoma | Locally Advanced Cholangiocarcinoma

United States
National Cancer Institute (NCI)

Completed

Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer

Stage III Intrahepatic Cholangiocarcinoma AJCC v8 | Gallbladder Carcinoma | Metastatic Cholangiocarcinoma | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Unresectable Cholangiocarcinoma

United States
City of Hope Medical Center

Recruiting

Detecting Lymph Node Metastasis in Intrahepatic Cholangiocarcinoma (LyMIC) (LyMIC)

Cholangiocarcinoma | Cholangiocarcinoma, Intrahepatic | Cholangiocarcinoma Resectable | Cholangiocarcinoma; Liver

United States, Japan
Mayo Clinic
National Cancer Institute (NCI)

Withdrawn

Ricolinostat, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable or Metastatic Cholangiocarcinoma

Unresectable Extrahepatic Bile Duct Carcinoma | Recurrent Cholangiocarcinoma | Non-Resectable Cholangiocarcinoma | Stage III Intrahepatic Cholangiocarcinoma | Stage IIIA Hilar Cholangiocarcinoma | Stage IIIB Hilar Cholangiocarcinoma | Stage IVA Hilar Cholangiocarcinoma | Stage IVA Intrahepatic Cholangiocarcinoma and other conditions

United States
Halozyme Therapeutics

Terminated

Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma

Cholangiocarcinoma Non-resectable | Cholangiocarcinoma, Extrahepatic | Cholangiocarcinoma, Intrahepatic | Gallbladder Adenocarcinoma

United States, Korea, Republic of, Thailand
Beth Israel Deaconess Medical Center
Dana-Farber Cancer Institute; AstraZeneca; Sirtex Medical

Recruiting

Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio

Cholangiocarcinoma | Bile Duct Cancer | Cholangiocarcinoma Non-resectable | Cholangiocarcinoma Metastatic | Metastatic Intrahepatic Cholangiocarcinoma

United States
Incyte Corporation

Recruiting

A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma (FIGHT-302)

Metastatic Cholangiocarcinoma | Unresectable Cholangiocarcinoma

United States, Canada, Belgium, France, Germany, Italy, China, Spain, Japan, United Kingdom, Netherlands, Switzerland, Austria, Denmark, Finland, Ireland, Israel, Norway, Sweden
Kura Oncology, Inc.

Completed

Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations

Thyroid Cancer | Squamous Cell Carcinoma Head and Neck Cancer (HNSCC) | HRAS Mutant Tumor | Other Squamous Cell Carcinoma (SCC) With HRAS Mutant Tumor

Spain, United States, Korea, Republic of, France, Belgium, Germany, Greece, Italy, Netherlands, United Kingdom
Memorial Sloan Kettering Cancer Center

Active, not recruiting

Hepatic Arterial Infusion (HAI) With Floxuridine (FUDR) and Dexamethasone (Dex) Combined With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma (ICC)

Intrahepatic Cholangiocarcinoma | Cholangiocellular Carcinoma | Peripheral Cholangiocarcinoma | Cholangiolar Carcinoma

United States
Memorial Sloan Kettering Cancer Center
Washington University School of Medicine; Ohio State University; University of...

Completed

Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Gemcitabine as Adjuvant Treatment After Resection of Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma | Peripheral Cholangiocarcinoma | Cholangiolar Carcinoma | Cholangiocellular Carcinoma) (ICC)

United States
NRG Oncology
National Cancer Institute (NCI)

Terminated

Radiation Therapy vs. Observation Following Gemcitabine and Cisplatin for Inoperable Localized Liver Cancer

Stage III Intrahepatic Cholangiocarcinoma | Stage IVA Intrahepatic Cholangiocarcinoma

United States, Canada
Inova Health Care Services

Not yet recruiting

The Purpose of This Research Study is to See if Combining Gemcitabine, Cisplatin and Durvalumab Chemotherapy Treatments With a Direct Tumor Therapy Yittrium-90 (Y-90) Will Work Better Together to Shrink Tumors and Control Cancer

Intrahepatic Cholangiocarcinoma

United States
Medical University of South Carolina

Active, not recruiting

90Y Transarterial Radioembolization (TARE) Plus Gemcitabine and Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma

United States
M.D. Anderson Cancer Center

Recruiting

A Single-Arm Study of Pembrolizumab With Gemcitabine and Cisplatin as Perioperative Therapy for Potentially Resectable Intrahepatic Cholangiocarcinoma

Cholangiocarcinoma

United States
University of Alabama at Birmingham

Terminated

Durvalumab and Tremelimumab With Platinum-based Chemotherapy in Intrahepatic Cholangiocarcinoma (ICC) (ICC)

Cholangiocarcinoma

United States
Massachusetts General Hospital
Bristol-Myers Squibb; TargetCancer Foundation

Completed

Phase II Trial of Dasatinib in Patients With Isocitrate Dehydrogenase (IDH)-Mutant Advanced Intrahepatic Cholangiocarcinoma

Cholangiocarcinoma

United States
Basilea Pharmaceutica

Completed

Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma (FIDES-01)

Intrahepatic Cholangiocarcinoma | Combined Hepatocellular and Cholangiocarcinoma

Canada, United States, Spain, Belgium, Italy, Korea, Republic of, Germany, Switzerland, France, United Kingdom, Ireland
Medivir

Active, not recruiting

A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations

Hepatocellular Carcinoma | Intrahepatic Cholangiocarcinoma | Liver Metastases

Korea, Republic of, Spain, Belgium, United Kingdom

Clinical Trials on IDH1-mutant Cholangiocarcinoma in United Kingdom

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Germany

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations